Literature DB >> 24246502

CMV-specific CD8+ T-cell function is not impaired in chronic lymphocytic leukemia.

G Doreen te Raa1, Maria Fernanda Pascutti, Juan J García-Vallejo, Emilie Reinen, Ester B M Remmerswaal, Ineke J M ten Berge, René A W van Lier, Eric Eldering, Marinus H J van Oers, Sanne H Tonino, Arnon P Kater.   

Abstract

In chronic lymphocytic leukemia (CLL), CD8(+) T cells exhibit features of exhaustion and impaired functionality. Yet, reactivations of latent viruses such as cytomegalovirus (CMV) are uncommon in untreated CLL, suggesting that antiviral responses are uncompromised. We analyzed phenotypical and functional characteristics of CMV-specific CD8(+) T cells in CLL patients in comparison with age-matched healthy controls (HCs). Despite increased expression of the inhibitory receptors PD1, CD160, and CD244 on total CD8(+) T cells in CLL, expression levels of these markers were decreased on CMV-tetramer(+)CD8(+) T cells. Second, cytokine production upon stimulation with both phorbol 12-myristate 13-acetate/ionomycin and CMV-peptide-loaded antigen-presenting cells was intact in CMV-tetramer(+)CD8(+) T cells. Third, CMV-tetramer(+)CD8(+) T cells of CLL patients and HCs were equally effective in killing CMV-peptide-loaded target cells. Finally, quantitative imaging flow cytometry revealed that the proportion of CD8(+) T cells forming immunologic synapses with CMV-peptide-loaded B cells was intact. In conclusion, despite evidence for global T-cell dysfunction in CLL, we show here that CLL-derived CMV-specific CD8(+) T cells display lower expression of exhaustion markers and are functionally intact. These data indicate that the changes in the T-cell compartment in CLL may be more heterogeneous than presently assumed.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24246502     DOI: 10.1182/blood-2013-08-518183

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  24 in total

1.  Mechanisms of PD-L1/PD-1-mediated CD8 T-cell dysfunction in the context of aging-related immune defects in the Eµ-TCL1 CLL mouse model.

Authors:  Fabienne McClanahan; John C Riches; Shaun Miller; William P Day; Eleni Kotsiou; Donna Neuberg; Carlo M Croce; Melania Capasso; John G Gribben
Journal:  Blood       Date:  2015-05-15       Impact factor: 22.113

Review 2.  Emerging role of BCR signaling inhibitors in immunomodulation of chronic lymphocytic leukemia.

Authors:  Kamira Maharaj; Eva Sahakian; Javier Pinilla-Ibarz
Journal:  Blood Adv       Date:  2017-09-26

3.  Chronic lymphocytic leukemia cells impair mitochondrial fitness in CD8+ T cells and impede CAR T-cell efficacy.

Authors:  Jaco A C van Bruggen; Anne W J Martens; Joseph A Fraietta; Tom Hofland; Sanne H Tonino; Eric Eldering; Mark-David Levin; Peter J Siska; Sanne Endstra; Jeffrey C Rathmell; Carl H June; David L Porter; J Joseph Melenhorst; Arnon P Kater; Gerritje J W van der Windt
Journal:  Blood       Date:  2019-05-10       Impact factor: 22.113

4.  PD-L1 checkpoint blockade prevents immune dysfunction and leukemia development in a mouse model of chronic lymphocytic leukemia.

Authors:  Fabienne McClanahan; Bola Hanna; Shaun Miller; Andrew James Clear; Peter Lichter; John G Gribben; Martina Seiffert
Journal:  Blood       Date:  2015-03-23       Impact factor: 22.113

Review 5.  Microenvironment interactions and B-cell receptor signaling in Chronic Lymphocytic Leukemia: Implications for disease pathogenesis and treatment.

Authors:  Elisa Ten Hacken; Jan A Burger
Journal:  Biochim Biophys Acta       Date:  2015-07-17

Review 6.  Improving therapy of chronic lymphocytic leukemia with chimeric antigen receptor T cells.

Authors:  Joseph A Fraietta; Robert D Schwab; Marcela V Maus
Journal:  Semin Oncol       Date:  2016-02-09       Impact factor: 4.929

Review 7.  SLAMF6 in health and disease: Implications for therapeutic targeting.

Authors:  Burcu Yigit; Ninghai Wang; Roland W Herzog; Cox Terhorst
Journal:  Clin Immunol       Date:  2018-10-23       Impact factor: 3.969

8.  Intrinsic Resistance of Chronic Lymphocytic Leukemia Cells to NK Cell-Mediated Lysis Can Be Overcome In Vitro by Pharmacological Inhibition of Cdc42-Induced Actin Cytoskeleton Remodeling.

Authors:  Hannah Wurzer; Liza Filali; Céline Hoffmann; Max Krecke; Andrea Michela Biolato; Jérôme Mastio; Sigrid De Wilde; Jean Hugues François; Anne Largeot; Guy Berchem; Jérôme Paggetti; Etienne Moussay; Clément Thomas
Journal:  Front Immunol       Date:  2021-05-24       Impact factor: 7.561

Review 9.  PD-1 expression and clinical PD-1 blockade in B-cell lymphomas.

Authors:  Zijun Y Xu-Monette; Jianfeng Zhou; Ken H Young
Journal:  Blood       Date:  2017-11-08       Impact factor: 25.476

10.  T cells are functionally not impaired in AML: increased PD-1 expression is only seen at time of relapse and correlates with a shift towards the memory T cell compartment.

Authors:  Frauke M Schnorfeil; Felix S Lichtenegger; Katharina Emmerig; Miriam Schlueter; Julia S Neitz; Rika Draenert; Wolfgang Hiddemann; Marion Subklewe
Journal:  J Hematol Oncol       Date:  2015-07-30       Impact factor: 17.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.